drugset
drugset / Trial / NCT04326283

Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT04326283 ↗

Phase 1/2 Terminated 23 enrolled Genuv Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of trametinib (SNR1611) in the treatment of amyotrophic lateral sclerosis.

Timeline

Start
2020-04-02
Primary completion
2023-04-28
Completion
2023-04-28

Outcome

Outcome not reported

Stopped: “Terminated as it is considered that necessary data have been collected”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Riluzole Small molecule 50 mg —
Subject Trametinib Small molecule 0.5 mg —
Subject Trametinib Small molecule 1 mg —

Indications

amyotrophic lateral sclerosis